Navigation Links
Wound Management Technologies, Inc. Announces a Published Case Study
Date:11/20/2008

CellerateRx(R) is FDA cleared for acute and chronic wounds which include but are not limited to: diabetic ulcers, venous stasis ulcers, ulcers due to arterial insufficiency, pressure ulcers stages I-IV, surgical wounds, traumatic wounds, superficial wounds, and 1st and 2nd degree burns. It comes in two forms, a powder which is about 95% collagen, and a gel which is about 65% collagen, and contains no additives or synthetics. CellerateRx(R) is manufactured in the United States.

About Wound Management Technologies, Inc.:

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at www.Celleraterx.com .

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other
'/>"/>

SOURCE Wound Management Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
2. Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011
3. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
4. MUSC Spin-Off Company to Test Regenerative Wound Healing Gel
5. Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM)
6. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
7. Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device
8. Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA
9. Cleveland Clinic and Rutgers to Lead Newly Formed Institute for War Wounded
10. Derma Sciences Announces Agreement With MedAssets for MEDIHONEY(TM) Wound & Burn Dressings
11. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 3$2.4 million stimulus fuels effort to regenerate injured spinal cords 4Delivering medicine directly into a tumor 2Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 1Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 2Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 3First and Only Weaning Product Based on 100 25 Non Allergenic Amino Acids Specifically Designed for Children With Cows Milk Protein Allergy and Multip 48577 1First and Only Weaning Product Based on 100 25 Non Allergenic Amino Acids Specifically Designed for Children With Cows Milk Protein Allergy and Multip 48577 2First and Only Weaning Product Based on 100 25 Non Allergenic Amino Acids Specifically Designed for Children With Cows Milk Protein Allergy and Multip 48577 3Public Call for Participation on National Board of Certification for Medical Interpreters 48574 1Public Call for Participation on National Board of Certification for Medical Interpreters 48574 2Public Call for Participation on National Board of Certification for Medical Interpreters 48574 3